

# ***Lama2 Cas9-KO Strategy***

Designer: Daohua Xu

# Project Overview

**Project Name**

***Lama2***

**Project type**

**Cas9-KO**

**Strain background**

**C57BL/6JGpt**

# Knockout strategy

This model will use CRISPR/Cas9 technology to edit the *Lama2* gene. The schematic diagram is as follows:



- The *Lama2* gene has 8 transcripts. According to the structure of *Lama2* gene, exon2-exon3 of *Lama2-201* (ENSMUST00000092639.11) transcript is recommended as the knockout region. The region contains 284bp coding sequence. Knock out the region will result in disruption of protein function.
- In this project we use CRISPR/Cas9 technology to modify *Lama2* gene. The brief process is as follows: CRISPR/Cas9 system

- According to the existing MGI data, Homozygotes for targeted and spontaneous mutations exhibit progressive growth retardation, ataxia, muscle atrophy and degeneration, infertility, and premature lethality. Muscle fiber degeneration is evident as early as the first week of life.
- The *Lama2* gene is located on the Chr10. If the knockout mice are crossed with other mice strains to obtain double gene positive homozygous mouse offspring, please avoid the two genes on the same chromosome.
- This Strategy is designed based on genetic information in existing databases. Due to the complexity of biological processes, all risk of the gene knockout on gene transcription, RNA splicing and protein translation cannot be predicted at the existing technology level.



# Gene information (NCBI)

## Lama2 laminin, alpha 2 [Mus musculus (house mouse)]

Gene ID: 16773, updated on 19-Mar-2019

### Summary




<b>Official Symbol</b>	Lama2 provided by <a href="#">MGI</a>
<b>Official Full Name</b>	laminin, alpha 2 provided by <a href="#">MGI</a>
<b>Primary source</b>	<a href="#">MGI:MGI:99912</a>
<b>See related</b>	<a href="#">Ensembl:ENSMUSG00000019899</a>
<b>Gene type</b>	protein coding
<b>RefSeq status</b>	VALIDATED
<b>Organism</b>	<a href="#">Mus musculus</a>
<b>Lineage</b>	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae; Murinae; Mus; Mus
<b>Also known as</b>	5830440B04, dy, mKIAA4087, mer, merosin
<b>Expression</b>	Broad expression in bladder adult (RPKM 7.3), heart adult (RPKM 7.3) and 22 other tissues <a href="#">See more</a>
<b>Orthologs</b>	<a href="#">human</a> <a href="#">all</a>

# Transcript information (Ensembl)


The gene has 8 transcripts,all transcripts are shown below:

Name	Transcript ID	bp	Protein	Biotype	CCDS	UniProt	Flags
Lama2-201	<a href="#">ENSMUST00000092639.11</a>	9614	<a href="#">3118aa</a>	Protein coding	<a href="#">CCDS48526</a>	<a href="#">Q60675</a>	TSL:5 GENCODE basic APPRIS P1
Lama2-207	<a href="#">ENSMUST00000189575.1</a>	4244	<a href="#">1349aa</a>	Protein coding	-	<a href="#">A0A087WRP2</a>	TSL:5 GENCODE basic
Lama2-208	<a href="#">ENSMUST00000219763.1</a>	3383	<a href="#">1127aa</a>	Protein coding	-	<a href="#">A0A1W2P7N3</a>	CDS 5' incomplete TSL:5
Lama2-205	<a href="#">ENSMUST00000187535.1</a>	328	No protein	Processed transcript	-	-	TSL:1
Lama2-203	<a href="#">ENSMUST00000186279.1</a>	6203	No protein	Retained intron	-	-	TSL:1
Lama2-202	<a href="#">ENSMUST00000185839.6</a>	2740	No protein	Retained intron	-	-	TSL:1
Lama2-204	<a href="#">ENSMUST00000186965.6</a>	1687	No protein	Retained intron	-	-	TSL:1
Lama2-206	<a href="#">ENSMUST00000188963.1</a>	643	No protein	Retained intron	-	-	TSL:3

The strategy is based on the design of *Lama2-201* transcript,The transcription is shown below




# Genomic location distribution






# Protein domain



# Mouse phenotype description(MGI )



*Phenotypes affected by the gene are marked in blue. Data quoted from MGI database(<http://www.informatics.jax.org/>).*

According to the existing MGI data, Homozygotes for targeted and spontaneous mutations exhibit progressive growth retardation, ataxia, muscle atrophy and degeneration, infertility, and premature lethality. Muscle fiber degeneration is evident as early as the first week of life.

If you have any questions, you are welcome to inquire.

Tel: 400-9660890

